Document Detail


Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration.
MedLine Citation:
PMID:  20554607     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To investigate the effect of changes in retinal morphology on contrast sensitivity and reading ability in patients with neovascular age-related macular degeneration (AMD) in the Avastin (bevacizumab; Genentech, South San Francisco, CA) for choroidal neovascularization (ABC) Trial.
METHODS: Contrast sensitivity obtained with Pelli-Robson charts, reading ability assessed with Minnesota Reading charts, and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) obtained by protocol refraction, were recorded. Raw Stratus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed with the publicly available software OCTOR, which allows precise delineation of any retinal compartment of interest. Thickness and volume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment epithelium detachment, and the resulting measurements were correlated with each visual function parameter.
RESULTS: One hundred twenty-two patients with newly diagnosed neovascular AMD and enrolled in the ABC Trial, were evaluated. Increased subretinal tissue volume correlated with decreased contrast sensitivity (Pearson's correlation coefficient, r = -0.4944, P = 0.001). A modest correlation was detected between SRF volume and contrast sensitivity (r = -0.2562, P = 0.004). Increased retinal thickness at the foveal center also correlated with decreased visual function (ETDRS VA: r = -0.4530, P < 0.001).
CONCLUSIONS: The strongest correlation detected between the functional parameters assessed and any of the OCT-derived morphologic parameters was that between decreased contrast sensitivity and increased subretinal tissue. In the future, assessment of contrast sensitivity and reading ability, in combination with quantitative subanalysis of retinal compartments, may lead to the identification of parameters relevant to functional improvement and ultimate prognosis in patients with newly diagnosed neovascular AMD (www.controlled-trials.com number, ISRCTN83325075).
Authors:
Pearse A Keane; Praveen J Patel; Yanling Ouyang; Fred K Chen; Felicia Ikeji; Alexander C Walsh; Adnan Tufail; Srinivas R Sadda
Related Documents :
7545047 - Treatment of choroidal neovascularization in age-related macular degeneration with inte...
11931787 - Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs ...
15279727 - Preventive versus treatment effect of ag3340, a potent matrix metalloproteinase inhibit...
17511757 - Treatment of choroidal neovascularization using intravitreal bevacizumab.
18061747 - Sleep preoccupation in poor sleepers: psychometric properties of the sleep preoccupatio...
20922037 - Optic disc measurements using the heidelberg retina tomograph in amblyopia.
Publication Detail:
Type:  Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-06-16
Journal Detail:
Title:  Investigative ophthalmology & visual science     Volume:  51     ISSN:  1552-5783     ISO Abbreviation:  Invest. Ophthalmol. Vis. Sci.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-28     Completed Date:  2010-12-07     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7703701     Medline TA:  Invest Ophthalmol Vis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5431-7     Citation Subset:  IM    
Affiliation:
Doheny Image Reading Center, Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
Data Bank Information
Bank Name/Acc. No.:
ISRCTN/ISRCTN83325075
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide / therapeutic use
Choroidal Neovascularization / diagnosis,  drug therapy,  physiopathology*
Contrast Sensitivity / physiology*
Cross-Sectional Studies
Double-Blind Method
Female
Humans
Macular Degeneration / diagnosis,  drug therapy,  physiopathology*
Male
Middle Aged
Photochemotherapy
Reading*
Retina / pathology*
Subretinal Fluid
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Grant Support
ID/Acronym/Agency:
EY03040/EY/NEI NIH HHS; R01 EY014375/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 2S9ZZM9Q9V/bevacizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy...
Next Document:  Interaction of corneal nociceptive stimulation and lacrimal secretion.